Evidence map›Paper›PMID 35896117›Full record

ArticleAmerican journal of human genetics2022

Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis.

Hugo Lemoine, Loann Raud, François Foulquier, John A Sayer, Baptiste Lambert, Eric Olinger, Siriane Lefèvre, Bertrand Knebelmann, Peter C Harris, Pascal Trouvé and 16 more

Open access · greenAbstract read
In one paragraph

Article in American journal of human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Monogenic Etiologies of Kidney Cysts in the Pediatric Population: An Observational Cohort Study.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Observational
  6. A Ciliary Phosphoinositide Pathway Regulates the Dosage of Polycystins in Primary Cilia.Journal of the American Society of Nephrology : JASN · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Glycosylation in kidney diseases.Precision clinical medicine · 2025
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Extrarenal manifestations in inherited kidney diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 16 institutions in 3 countries.

Hugo LemoineUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France.
Loann RaudUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France.
François FoulquierUniv. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, 59000 Lille, France.
John A SayerTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE1 3BZ, UK; The Newcastle upon Tyne Hospitals NHS Foundation Trust, Renal Services, Freeman Road, Newcastle Upon Tyne NE7 7DN, UK; NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle Upon Tyne NE4 5PL, UK.
Baptiste LambertUniv. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, 59000 Lille, France.
Eric OlingerTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE1 3BZ, UK.
Siriane LefèvreUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France; Service de Néphrologie, Hôpital de Lorient, 56322 Lorient, France.
Bertrand KnebelmannService de Néphrologie et Transplantation rénale, Hôpital Necker, APHP, Université de Paris, Paris, France.
Peter C HarrisDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55902, USA.
Pascal TrouvéUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France.
Aurore DesprèsService de Génétique moléculaire, CHRU Brest, 29609 Brest, France.
Gabrielle DuneauAssociation des Urémiques de Bretagne, Lorient, France.
Marie MatignonUniversity Paris Est Créteil, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Fédération Hospitalo-Universitaire "Innovative Therapy for Immune Disorders", Créteil, France.
Anais PoyetAssociation Régionale d'Aide aux Urémiques du Centre Ouest (ARAUCO), Bourges, France.
Noémie Jourde-ChicheCentre de Néphrologie et Transplantation Rénale, Hôpital de la Conception (APHM), Marseille, France.
Dominique GuerrotService de Néphrologie, Dialyse et Transplantation, CHU de Rouen, Rouen, France.
Sandrine LemoineNéphrologie, Dialyse, Hypertension artérielle et Exploration Fonctionnelle rénale, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Guillaume SeretNéphrologie-Dialyse, Association ECHO, Le Mans, France.
Miguel Barroso-GilTranslational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE1 3BZ, UK.
Coralie BinghamRoyal Devon and Exeter NHS Foundation Trust, Exeter EX2 5DW, UK.
Rodney GilbertSouthampton Children's Hospital, University of Southampton, Southampton SO16 6YD, UK.
Genomics England Research Consortium
Genkyst Study Group
Yannick Le MeurUniv Brest, UMR 1227, LBAI, Labex IGO, 29200 Brest, France; Service de Néphrologie, Hémodialyse et Transplantation rénale, CHRU Brest, 29609 Brest, France.
Marie-Pierre AudrézetUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France; Service de Génétique moléculaire, CHRU Brest, 29609 Brest, France.
Emilie Cornec-Le GallUniv. Brest, Inserm, UMR 1078, GGB, 29200 Brest, France; Service de Néphrologie, Hémodialyse et Transplantation rénale, CHRU Brest, 29609 Brest, France. Electronic address: emilie.cornec-legall@chu-brest.fr.
Inserm · FRCentre National de la Recherche Scientifique · FRNewcastle University · GBAssistance Publique – Hôpitaux de Paris · FRAssociation pour l'Utilisation du Rein Artificiel · FRCentre Hospitalier du Mans · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Universitaire de Rouen · FRHôpital de la Conception · FRHospices Civils de Lyon · FRMayo Clinic · USNewcastle upon Tyne Hospitals NHS Foundation Trust · GBRoyal Devon & Exeter NHS Foundation Trust · GBSouthampton Children's Hospital · GBUniversité de Bretagne Occidentale · FRUniversité de Bretagne Sud · FR

Funding

ADPKD:Disease Spectrum &Genotype-Phenotype CorrelationsR01DK058816 · NIDDK · MAYO CLINIC ROCHESTER · PI Peter C. Harris · 2001 to 2026
$11.3M
NIDDK NIH HHS R01 DK058816
6 · The paper itself

Abstract

Disorders of the autosomal dominant polycystic kidney disease (ADPKD) spectrum are characterized by the development of kidney cysts and progressive kidney function decline. PKD1 and PKD2, encoding polycystin (PC)1 and 2, are the two major genes associated with ADPKD; other genes include IFT140, GANAB, DNAJB11, and ALG9. Genetic testing remains inconclusive in ∼7% of the families. We performed whole-exome sequencing in a large multiplex genetically unresolved (GUR) family affected by ADPKD-like symptoms and identified a monoallelic frameshift variant (c.703_704delCA) in ALG5. ALG5 encodes an endoplasmic-reticulum-resident enzyme required for addition of glucose molecules to the assembling N-glycan precursors. To identify additional families, we screened a cohort of 1,213 families with ADPKD-like and/or autosomal-dominant tubulointerstitial kidney diseases (ADTKD), GUR (n = 137) or naive to genetic testing (n = 1,076), by targeted massively parallel sequencing, and we accessed Genomics England 100,000 Genomes Project data. Four additional families with pathogenic variants in ALG5 were identified. Clinical presentation was consistent in the 23 affected members, with non-enlarged cystic kidneys and few or no liver cysts; 8 subjects reached end-stage kidney disease from 62 to 91 years of age. We demonstrate that ALG5 haploinsufficiency is sufficient to alter the synthesis of the N-glycan chain in renal epithelial cells. We also show that ALG5 is required for PC1 maturation and membrane and ciliary localization and that heterozygous loss of ALG5 affects PC1 maturation. Overall, our results indicate that monoallelic variants of ALG5 lead to a disorder of the ADPKD-spectrum characterized by multiple small kidney cysts, progressive interstitial fibrosis, and kidney function decline.

Indexed as

CystsPolycystic Kidney, Autosomal DominantExome SequencingFibrosisHumansKidneyMutationALG5autosomal-dominant polycystic kidney diseaseautosomal dominant tubulo-interstitial kidney diseaseN-linked glycosylationrenal insufficiency

Identifiers

PMID35896117
PMCPMC9388391
OpenAlexW4288045253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.